These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14511643)

  • 21. The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice.
    Schürmann C; Linke A; Engelmann-Pilger K; Steinmetz C; Mark M; Pfeilschifter J; Klein T; Frank S
    J Pharmacol Exp Ther; 2012 Jul; 342(1):71-80. PubMed ID: 22493041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA; Gallwitz B
    Best Pract Res Clin Endocrinol Metab; 2009 Aug; 23(4):479-86. PubMed ID: 19748065
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterisation of human dipeptidyl peptidase IV expressed in Pichia pastoris. A structural and mechanistic comparison between the recombinant human and the purified porcine enzyme.
    Bär J; Weber A; Hoffmann T; Stork J; Wermann M; Wagner L; Aust S; Gerhartz B; Demuth HU
    Biol Chem; 2003 Dec; 384(12):1553-63. PubMed ID: 14719797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peptide degradation and the role of DPP-4 inhibitors in the treatment of type 2 diabetes.
    Deacon CF
    Peptides; 2018 Feb; 100():150-157. PubMed ID: 29412814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice.
    Lu Y; Lu P; Wang Y; Fang X; Wu J; Wang X
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30646613
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-talk between the dipeptidyl peptidase-4 and stromal cell-derived factor-1 in stem cell homing and myocardial repair: Potential impact of dipeptidyl peptidase-4 inhibitors.
    Anderluh M; Kocic G; Tomovic K; Kocic R; Deljanin-Ilic M; Smelcerovic A
    Pharmacol Ther; 2016 Nov; 167():100-107. PubMed ID: 27484974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancing incretin action for the treatment of type 2 diabetes.
    Drucker DJ
    Diabetes Care; 2003 Oct; 26(10):2929-40. PubMed ID: 14514604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Food protein hydrolysates as a source of dipeptidyl peptidase IV inhibitory peptides for the management of type 2 diabetes.
    Power O; Nongonierma AB; Jakeman P; FitzGerald RJ
    Proc Nutr Soc; 2014 Feb; 73(1):34-46. PubMed ID: 24131508
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.
    Green BD; Gault VA; Irwin N; Mooney MH; Bailey CJ; Harriott P; Greer B; Flatt PR; O'Harte FP
    Biol Chem; 2003 Dec; 384(12):1543-51. PubMed ID: 14719796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors.
    Holst JJ
    Adv Exp Med Biol; 2003; 524():263-79. PubMed ID: 12675249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo.
    Kim JG; Baggio LL; Bridon DP; Castaigne JP; Robitaille MF; Jetté L; Benquet C; Drucker DJ
    Diabetes; 2003 Mar; 52(3):751-9. PubMed ID: 12606517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The metabolite generated by dipeptidyl-peptidase 4 metabolism of glucagon-like peptide-1 has no influence on plasma glucose levels in patients with type 2 diabetes.
    Zander M; Madsbad S; Deacon CF; Holst JJ
    Diabetologia; 2006 Feb; 49(2):369-74. PubMed ID: 16385384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1.
    Lee SH; Lee S; Youn YS; Na DH; Chae SY; Byun Y; Lee KC
    Bioconjug Chem; 2005; 16(2):377-82. PubMed ID: 15769092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chitosan-based therapeutic nanoparticles for combination gene therapy and gene silencing of in vitro cell lines relevant to type 2 diabetes.
    Jean M; Alameh M; De Jesus D; Thibault M; Lavertu M; Darras V; Nelea M; Buschmann MD; Merzouki A
    Eur J Pharm Sci; 2012 Jan; 45(1-2):138-49. PubMed ID: 22085632
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both mediators of the degradation of glucagon-like peptide 1 in the anaesthetised pig.
    Plamboeck A; Holst JJ; Carr RD; Deacon CF
    Diabetologia; 2005 Sep; 48(9):1882-90. PubMed ID: 16025254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel GLP-1 analog, BPI3006, with potent DPP IV resistance and good glucoregulatory effect.
    Li C; Huan Y; Shen N; Ji L; Sun S; Liu S; Liu Q; Gao L; Tan F; Wang Y; Shen Z
    Biochem Biophys Res Commun; 2010 Oct; 400(4):563-8. PubMed ID: 20804731
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.
    Omar B; Ahrén B
    Diabetes; 2014 Jul; 63(7):2196-202. PubMed ID: 24962916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion.
    Deacon CF; Plamboeck A; Møller S; Holst JJ
    Am J Physiol Endocrinol Metab; 2002 Apr; 282(4):E873-9. PubMed ID: 11882507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
    Uchii M; Sakai M; Hotta Y; Saeki S; Kimoto N; Hamaguchi A; Kitayama T; Kunori S
    J Pharmacol Sci; 2017 Nov; 135(3):126-130. PubMed ID: 29113790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.